GNLX
Genelux·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Revenue Decline
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Three Black Crows
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GNLX
Genelux Corporation
A company researching a leading generation of oncolytic virus immunotherapies
Life Science Tools and Services
09/04/2001
01/26/2023
NASDAQ Stock Exchange
24
12-31
Common stock
2625 Townsgate Road, Suite 230, Westlake Village, California 91361
--
Genelux Corporation, a Delaware corporation, was founded on September 4, 2001 and is a biomedical company located in Westlake Village, California. The company is engaged in the research and development of cancer diagnosis and treatment solutions, and there is currently no effective treatment. The company focuses on the development of cancer treatments designed to generate personalized multi-pronged attacks to overwhelm the complex defense mechanisms of tumors.
Company Financials
EPS
GNLX has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.21, meeting expectations. The chart below visualizes how GNLX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
